Solventum (SOLV) Competitors

$62.38
+0.82 (+1.33%)
(As of 05/17/2024 ET)

SOLV vs. PODD, TFX, SWAV, GMED, PEN, GKOS, INSP, HAE, MMSI, and BAX

Should you be buying Solventum stock or one of its competitors? The main competitors of Solventum include Insulet (PODD), Teleflex (TFX), Shockwave Medical (SWAV), Globus Medical (GMED), Penumbra (PEN), Glaukos (GKOS), Inspire Medical Systems (INSP), Haemonetics (HAE), Merit Medical Systems (MMSI), and Baxter International (BAX). These companies are all part of the "surgical & medical instruments" industry.

Solventum vs.

Solventum (NYSE:SOLV) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.

Insulet has a net margin of 13.14% compared to Solventum's net margin of 0.00%. Insulet's return on equity of 34.06% beat Solventum's return on equity.

Company Net Margins Return on Equity Return on Assets
SolventumN/A N/A N/A
Insulet 13.14%34.06%9.08%

In the previous week, Insulet had 21 more articles in the media than Solventum. MarketBeat recorded 25 mentions for Insulet and 4 mentions for Solventum. Solventum's average media sentiment score of 0.36 beat Insulet's score of 0.19 indicating that Solventum is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solventum
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Insulet
6 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral

Solventum currently has a consensus price target of $69.67, suggesting a potential upside of 11.68%. Insulet has a consensus price target of $239.44, suggesting a potential upside of 27.86%. Given Insulet's stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solventum
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Insulet
0 Sell rating(s)
3 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.82

Insulet received 712 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 66.05% of users gave Insulet an outperform vote while only 0.00% of users gave Solventum an outperform vote.

CompanyUnderperformOutperform
SolventumOutperform Votes
No Votes
Underperform Votes
4
100.00%
InsuletOutperform Votes
712
66.05%
Underperform Votes
366
33.95%

Insulet has higher revenue and earnings than Solventum.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SolventumN/AN/AN/AN/AN/A
Insulet$1.70B7.73$206.30M$3.3056.75

Summary

Insulet beats Solventum on 10 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SOLV vs. The Competition

MetricSolventumSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$10.77B$4.08B$5.30B$18.09B
Dividend YieldN/A1.99%43.94%3.44%
P/E RatioN/A17.14154.7026.23
Price / SalesN/A72.162,362.9311.57
Price / CashN/A48.6236.6019.45
Price / Book2.804.895.756.01
Net IncomeN/A$5.08M$106.86M$966.65M
7 Day Performance-2.13%2.24%1.41%1.85%
1 Month Performance0.34%3.39%4.29%7.14%
1 Year PerformanceN/A20.14%7.61%21.67%

Solventum Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PODD
Insulet
4.9396 of 5 stars
$165.90
-6.6%
$240.25
+44.8%
-38.2%$11.62B$1.70B50.273,000Gap Up
High Trading Volume
TFX
Teleflex
4.8229 of 5 stars
$203.93
-0.4%
$261.75
+28.4%
-11.2%$9.61B$3.00B32.7314,500Ex-Dividend
SWAV
Shockwave Medical
4.4426 of 5 stars
$330.55
+0.0%
$309.11
-6.5%
+19.4%$12.41B$730.23M77.231,468Positive News
GMED
Globus Medical
4.5136 of 5 stars
$64.72
+0.6%
$66.50
+2.8%
+13.5%$8.76B$1.57B101.135,000Insider Selling
Short Interest ↑
PEN
Penumbra
4.7976 of 5 stars
$212.28
+1.4%
$300.64
+41.6%
-35.4%$8.23B$1.06B89.574,200Insider Selling
GKOS
Glaukos
3.292 of 5 stars
$110.46
+2.6%
$108.64
-1.7%
+83.1%$5.56B$314.71M-38.35907Insider Selling
Short Interest ↑
INSP
Inspire Medical Systems
4.9151 of 5 stars
$167.83
-3.8%
$256.53
+52.9%
-48.7%$4.99B$624.80M-305.151,011Positive News
HAE
Haemonetics
3.9809 of 5 stars
$95.86
+3.5%
$108.67
+13.4%
+14.9%$4.87B$1.31B41.863,034
MMSI
Merit Medical Systems
4.6426 of 5 stars
$80.83
+0.9%
$92.78
+14.8%
-2.5%$4.70B$1.26B46.456,950Positive News
BAX
Baxter International
4.84 of 5 stars
$35.69
-0.7%
$45.73
+28.1%
-18.1%$18.19B$14.81B6.8660,000

Related Companies and Tools

This page (NYSE:SOLV) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners